immunology

News

Sobi cuts staff and buys Novimmune drug in refocus

Sobi has narrowed its focus to haematology and immunology, shedding staff and R&D projects in other areas whilst taking full control of a drug it licenses from Novimmune.

News

Merck bolts on another immunology firm with $773m Tilos deal

Merck & Co/MSD has agreed to buy privately held biotech Tilos Therapeutics for up to $773 million, its third pipeline-boosting deal in a little over four months.

Views & Analysis

CAR-Ts - a new weapon in the fight against cancer

CAR-T - or Chimeric Antigen Receptor T-cell therapies herald a new wave of therapies in cancer.

News

Novartis pays up to $1 billion for potential eczema drug

Swiss pharma Novartis is to pay up to $1 billion to Galapagos and MorphoSys for exclusive rights to a skin drug, which will further strengthen Novartis’s leadership position in the immunolo

News

Roche to buy rest of genetics firm Foundation Medicine

Roche has made an offer to buy the remaining shares in cancer genetics firm Foundation Medicine (FMI) for $2.4 billion.

News

More good news for AbbVie in rheumatoid arthritis

AbbVie has reported positive top-line results for its oral JAK1-selective inhibitor in rheumatoid arthritis (RA), bringing it closer to a potential new early treatment option for patients.

Sobi cuts staff and buys Novimmune drug in refocus

Merck bolts on another immunology firm with $773m Tilos deal

CAR-Ts - a new weapon in the fight against cancer

Novartis pays up to $1 billion for potential eczema drug

Roche to buy rest of genetics firm Foundation Medicine

More good news for AbbVie in rheumatoid arthritis

Consolidating data strategy for global success: Insights fro...

How to meet your physicians where they are online

immunology

Editor's Picks